Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148691 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 253
- Enrollment target
NCT03148691 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 253 participants.
The verdict
NCT03148691, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 253 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.
Interventions
- DRUG A-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2017-05-17 |
| Est. Completion | 2018-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148691
The ClinicalTrials.gov registry entry for NCT03148691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A-101 is the first listed.
NCT03148691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03148691 about?
NCT03148691 is a clinical study titled "A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis". The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.
What is the current status of trial NCT03148691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 253 participants. The study started on 2017-05-17. Estimated completion is 2018-04-03.
What interventions are being tested in trial NCT03148691?
The interventions under investigation include: A-101 (DRUG).
Who is sponsoring clinical trial NCT03148691?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.